BR122020014933B8 - Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico - Google Patents

Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico

Info

Publication number
BR122020014933B8
BR122020014933B8 BR122020014933A BR122020014933A BR122020014933B8 BR 122020014933 B8 BR122020014933 B8 BR 122020014933B8 BR 122020014933 A BR122020014933 A BR 122020014933A BR 122020014933 A BR122020014933 A BR 122020014933A BR 122020014933 B8 BR122020014933 B8 BR 122020014933B8
Authority
BR
Brazil
Prior art keywords
acid form
toluensulfonic
naphtalenodisulfonic
naphtalendisulphonic
benzenesulphonates
Prior art date
Application number
BR122020014933A
Other languages
English (en)
Other versions
BR122020014933B1 (pt
Inventor
Chestakova Alexandra
Gu Wei
Iding Hans
Li Jing
LINGHU Xin
MEIER Patrik
Sha Chunbo
Stults Jeffrey
Wang Youchu
Zhang Haiming
Zhang Jianqian
Zhang Tao
LIN Jinguang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR122020014933B1 publication Critical patent/BR122020014933B1/pt
Publication of BR122020014933B8 publication Critical patent/BR122020014933B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

A presente invenção se refere a um processo para a fabricação de um composto de Fórmula (VIIIa) e formas de sais de (VIIIa) em que Rc é um ácido sulfônico de arila.
BR122020014933A 2014-04-09 2015-04-08 Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico BR122020014933B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/075011 2014-04-09
CN2014075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (2)

Publication Number Publication Date
BR122020014933B1 BR122020014933B1 (pt) 2022-11-29
BR122020014933B8 true BR122020014933B8 (pt) 2022-12-13

Family

ID=54287327

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020014933A BR122020014933B8 (pt) 2014-04-09 2015-04-08 Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico
BR112016023391-3A BR112016023391B1 (pt) 2014-04-09 2015-04-08 Processo para a preparação de um composto de fórmula viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112016023391-3A BR112016023391B1 (pt) 2014-04-09 2015-04-08 Processo para a preparação de um composto de fórmula viii

Country Status (22)

Country Link
US (4) US20170022183A1 (pt)
EP (2) EP3129025B1 (pt)
JP (3) JP6723926B2 (pt)
KR (3) KR20230006043A (pt)
CN (3) CN112645927A (pt)
AR (1) AR099989A1 (pt)
AU (2) AU2015245743B2 (pt)
BR (2) BR122020014933B8 (pt)
CA (2) CA2945098C (pt)
ES (1) ES2733495T3 (pt)
HR (1) HRP20191306T1 (pt)
IL (2) IL248205B (pt)
MX (2) MX2016013162A (pt)
MY (2) MY196320A (pt)
NZ (1) NZ725450A (pt)
PL (1) PL3129025T3 (pt)
RU (1) RU2684102C2 (pt)
SG (1) SG11201608421XA (pt)
SI (1) SI3129025T1 (pt)
TW (2) TWI762806B (pt)
WO (1) WO2015154674A1 (pt)
ZA (1) ZA201607066B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
ES2733495T3 (es) 2014-04-09 2019-11-29 Genentech Inc Proceso para la fabricación de medicamentos
TN2018000119A1 (en) 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CN114746410A (zh) * 2019-12-05 2022-07-12 阿斯利康有限公司 用于生产式(i)的方法和中间体
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
AU2007229552C1 (en) * 2006-03-29 2013-06-13 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mGluR2 antagonists
WO2009061761A2 (en) * 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
WO2015130976A1 (en) * 2014-02-27 2015-09-03 Canon U.S.A., Inc. Placement apparatus
ES2733495T3 (es) 2014-04-09 2019-11-29 Genentech Inc Proceso para la fabricación de medicamentos

Also Published As

Publication number Publication date
IL268690A (en) 2019-10-31
TW201945358A (zh) 2019-12-01
HRP20191306T1 (hr) 2019-10-18
TW201620897A (zh) 2016-06-16
TWI678366B (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
CN111777594A (zh) 2020-10-16
EP3129025B1 (en) 2019-05-15
IL248205A0 (en) 2016-11-30
CN112645927A (zh) 2021-04-13
NZ725450A (en) 2022-08-26
US10611753B2 (en) 2020-04-07
AU2020220208A1 (en) 2020-09-10
AR099989A1 (es) 2016-08-31
SI3129025T1 (sl) 2019-08-30
AU2015245743A1 (en) 2016-10-27
BR112016023391A2 (pt) 2017-08-15
KR20160133566A (ko) 2016-11-22
CA2945098A1 (en) 2015-10-15
SG11201608421XA (en) 2016-11-29
JP6723926B2 (ja) 2020-07-15
EP3494971A1 (en) 2019-06-12
RU2016139286A3 (pt) 2018-10-26
IL248205B (en) 2019-09-26
JP2020114817A (ja) 2020-07-30
JP6974524B2 (ja) 2021-12-01
JP2017510620A (ja) 2017-04-13
RU2684102C2 (ru) 2019-04-04
CN106659721A (zh) 2017-05-10
BR112016023391A8 (pt) 2021-07-20
KR102490955B1 (ko) 2023-01-19
MY196320A (en) 2023-03-24
AU2015245743B2 (en) 2020-09-24
MX2016013162A (es) 2017-04-27
US20200190061A1 (en) 2020-06-18
US20170022183A1 (en) 2017-01-26
TWI762806B (zh) 2022-05-01
ES2733495T3 (es) 2019-11-29
BR112016023391B1 (pt) 2022-08-09
PL3129025T3 (pl) 2019-11-29
ZA201607066B (en) 2018-05-30
CN106659721B (zh) 2021-01-01
BR122020014933B1 (pt) 2022-11-29
JP2021167321A (ja) 2021-10-21
RU2016139286A (ru) 2018-05-15
CA2945098C (en) 2022-10-04
EP3129025A4 (en) 2018-01-17
WO2015154674A1 (en) 2015-10-15
MX2020010384A (es) 2022-05-19
AU2020220208B2 (en) 2022-03-17
US11098028B2 (en) 2021-08-24
US20190367484A1 (en) 2019-12-05
EP3129025A1 (en) 2017-02-15
KR20230006043A (ko) 2023-01-10
MY188526A (en) 2021-12-18
CA3167641A1 (en) 2015-10-15
US11066389B2 (en) 2021-07-20
US20180134685A1 (en) 2018-05-17
CN111777594B (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
BR122020014933B8 (pt) Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico
ECSP16088985A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
DK3122750T3 (da) Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
BR112016028773A2 (pt) processos para preparação de compostos antivirais
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
DK3235819T3 (da) Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CR20170005A (es) Derivados de insoindolina
DK3552017T3 (da) Forbindelser, der er anvendelige som ripk1-inhibitorer
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
BR112016027819A8 (pt) processo de preparação de derivados de tiazole
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
BR112019006963A2 (pt) método para preparar acetofenonas substituídas por ciclopropil
IN2014MU00195A (pt)
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
DOP2017000070A (es) Inhibidores cristalinos de bace

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2708 DE 29/11/2022, QUANTO AO ITEM (54) TITULO.